Cargando…
Short communication: Comments on hair disorders associated with dupilumab based on VigiBase
BACKGROUND: Dupilumab is a human antibody that blocks the signaling of both interleukin-4 and interleukin-13 receptors. It has been approved for the treatment of moderate-to-severe atopic dermatitis. However, several case reports have reported conflicting effects of dupilumab on alopecia. OBJECTIVES...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328572/ https://www.ncbi.nlm.nih.gov/pubmed/35895603 http://dx.doi.org/10.1371/journal.pone.0270906 |